European shares were unchanged on Friday, as losses in heavyweight healthcare shares were countered by an advance in oil and ...

The Sensex dropped 502 points on Friday to close at 81,758, while the Nifty slipped 143 points to end below the 25,000 mark ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

The fallers board was led by WPP, which slumped by 16% to its lowest level since 2009 after the marketing and advertising ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

Wave Life Sciences could offer significant upside if obesity candidate WVE-007 delivers strong human data. Check out the detailed analysis of WVE stock.

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the industry’s decline of 1.3%. The stock has also outperformed the sector in the ...

Despite all the noise around Tesla, its year-to-date stock performance boils down to three main developments that have dictated price action and sentiment. These are detailed below.